At the ACG meeting this week, a University of North Carolina at Chapel Hill researcher reported that scientists know infliximab treatment for Crohn's disease leads to significant weight gain, but that they still aren't sure why. The researcher also noted that some weight gain in Crohn's patients is desirable as these patients tend to be undernourished, but that the 60- to 75-pound gain in some patients brings added concerns about the health risks of obesity.

Related Summaries